Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
PTH analogs decreased 25(OH) vitamin D, increased 1,25(OH)2 vitamin D and eGFR.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis
Source: Article title.
Publisher article type: systematic-review
Source: Publisher publication metadata.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis
Review / evidence synthesis · Frontiers in Endocrinology · 2026
Original publication title
Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis
Copyright © 2026 Li, Zhang, Zhao and Ma.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To assess the efficacy and safety of parathyroid hormone(PTH) analogs alone as compared with the conventional therapy on HypoPTH, and assess its emphasis on patients’ health-related quality of life (HRQoL).
Source: PurposeAbstract: What methods does the paper describe?
Database (PubMed, Web of Science, Embase and Cochrane Library) were systematically searched until February 30, 2026. The primary outcomes were serum calcium and serum phosphate, while the secondary outcomes included 24-hour urinary calcium excretion, serum 25(OH)D, serum 1,25-dihydroxyvitamin D, calcium phosphate product, estimated glomerular filtration rate (eGFR), adverse events, and HRQoL. Meta-analysis was conducted using RevMan 5.4 and STATA 17.0.
Source: MethodsAbstract: Systematic Review Registration
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251089112.
Source: Systematic Review RegistrationAbstract: Results
Eleven studies were included. Compared to conventional therapy, PTH analogs therapy showed no difference in serum calcium (MD = -0.02 mmol/L; 95% CI, -0.14 to 0.11 mmol/L), serum phosphorus (MD = 0.08 mmol/L; 95% CI, -0.05 to 0.20 mmol/L) and 24-hour urinary calcium excretion (MD = 1.00 mmol; 95% CI, -1.84 to 3.84 mmol). PTH analogs decreased 25(OH) vitamin D, increased 1,25(OH)2 vitamin D and eGFR. Additionally, PTH analogs therapy significantly improved HRQoL as measured by the Short Form 36 (SF-36) Health Survey Questionnaire (MD = -7.35; 95% CI, -8.37 to -6.33).
Source: ResultsAbstract: Conclusion
In addition to the comparable control of serum calcium and serum phosphorus levels to conventional therapy, limited data indicate that PTH analogs treatment may be better in regulating the serum vitamin D and maintaining the eGFR for patients with HypoPTH. PTH analogs therapy also improves patients’ HRQoL.
Source: ConclusionAuthors’ abstract
Purpose
To assess the efficacy and safety of parathyroid hormone(PTH) analogs alone as compared with the conventional therapy on HypoPTH, and assess its emphasis on patients’ health-related quality of life (HRQoL).
Methods
Database (PubMed, Web of Science, Embase and Cochrane Library) were systematically searched until February 30, 2026. The primary outcomes were serum calcium and serum phosphate, while the secondary outcomes included 24-hour urinary calcium excretion, serum 25(OH)D, serum 1,25-dihydroxyvitamin D, calcium phosphate product, estimated glomerular filtration rate (eGFR), adverse events, and HRQoL. Meta-analysis was conducted using RevMan 5.4 and STATA 17.0.
Results
Eleven studies were included. Compared to conventional therapy, PTH analogs therapy showed no difference in serum calcium (MD = -0.02 mmol/L; 95% CI, -0.14 to 0.11 mmol/L), serum phosphorus (MD = 0.08 mmol/L; 95% CI, -0.05 to 0.20 mmol/L) and 24-hour urinary calcium excretion (MD = 1.00 mmol; 95% CI, -1.84 to 3.84 mmol). PTH analogs decreased 25(OH) vitamin D, increased 1,25(OH)2 vitamin D and eGFR. Additionally, PTH analogs therapy significantly improved HRQoL as measured by the Short Form 36 (SF-36) Health Survey Questionnaire (MD = -7.35; 95% CI, -8.37 to -6.33).
Conclusion
In addition to the comparable control of serum calcium and serum phosphorus levels to conventional therapy, limited data indicate that PTH analogs treatment may be better in regulating the serum vitamin D and maintaining the eGFR for patients with HypoPTH. PTH analogs therapy also improves patients’ HRQoL.
Systematic Review Registration
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251089112.
Publication and source details
Original title: Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis
Siting Li; Yuanfang Zhang; Li Zhao; Chao Ma
Frontiers in Endocrinology · 2026
* Correspondence: Chao Ma, mc_7419@hotmail.com†These authors have contributed equally to this work
‡ORCID: Siting Li, orcid.org/0009-0002-4642-4899
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:11:06.878115+00:00
DOI: 10.3389/fendo.2026.1847971 · PMC13372652